Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction Results From the ATLAS ACS-2-TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907904" target="_blank" >RIV/00216208:11120/13:43907904 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/13:N0000006
Result on the web
<a href="http://dx.doi.org/10.1016/j.jacc.2013.01.066" target="_blank" >http://dx.doi.org/10.1016/j.jacc.2013.01.066</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jacc.2013.01.066" target="_blank" >10.1016/j.jacc.2013.01.066</a>

Result language
angličtina
Original language name
Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction Results From the ATLAS ACS-2-TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)
Original language description
The present analysis reports on the pre-specified subgroup of ST-elevation myocardial infarction (STEMI) patients, in whom anticoagulant therapy has been of particular interest. In ATLAS ACS-2-TIMI-51 rivaroxaban reduced cardiovascular events across thespectrum of acute coronary syndrome (ACS). Seven thousand eight hundred seventeen patients in ATLAS ACS-2-TIMI 51 presented with a STEMI. After being stabilized (1 to 7 days), they underwent randomization to twice daily rivaroxaban 2.5 mg, rivaroxaban 5mg, or placebo. Data are presented as 2-year Kaplan-Meier rates, and for intention-to-treat (ITT) and modified ITT (mITT) analyses. Among STEMI patients, rivaroxaban reduced the primary efficacy endpoint of cardiovascular death, myocardial infarction, orstroke, compared with placebo (ITT: 8.4% vs. 10.6%, hazards ratio [HR]: 0.81, 95% confidence interval [CI]: 0.67 to 0.97, p = 0.019; mITT: 8.3% vs. 9.7%, HR: 0.85, 95% CI: 0.70 to 1.03, p = 0.09). This reduction emerged by 30 days (ITT a
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)